Want to see NXGL full AI Analyst Report?
NXGL Stock Chart & Stats
$1.64
-$0.06(-1.71%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.71%)
Day’s Range― - ―
52-Week Range$0.48 - $2.89
Previous CloseN/A
Volume27.00K
Average Volume (3M)50.95K
Market Cap
$6.12M
Enterprise Value$9.71M
Total Cash (Recent Filing)$208.00K
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,225,242
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit2.22
Enterprise Value/Ebitda-4.35
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Expanded Commercial Footprint Via BioNX AcquisitionThe BioNX acquisition brings six commercial-stage regenerative biomaterial products and an existing presence in roughly 500 U.S. hospitals. That immediate commercial scale and established reimbursement creates durable revenue channels, accelerates market access, and materially strengthens go-to-market capabilities versus organic expansion alone.
Strategic Financing And Sequence LifeScience PartnershipSequence LifeScience’s $5.5M strategic investment, board appointments and contract manufacturing role align capital, manufacturing and distribution capabilities with NexGel. This reduces execution friction for integration, provides operational capacity and adds governance expertise that should improve commercialization and product development durability.
Improving Gross Margins And Multi-year Revenue ScalingGross margins rising to about 39% TTM indicate improving unit economics in hydrogel products and license assets. Combined with multi-year revenue scaling, stronger product economics provide a credible path to operating leverage as fixed costs are absorbed, supporting sustainable profitability if SG&A is controlled.
Bears Say
Weak Cash Generation And Low Cash On HandThe company has reported negative operating and free cash flow roughly -$1.4M TTM and reported only about $1.8M cash on hand at the call. That limited liquidity constrains the firm's ability to fund integration, sales expansion and R&D without further financing, raising execution and dilution risk over the next several months.
Rising Leverage And Convertible ObligationsLeverage has increased materially (debt ≈ equity, debt-to-equity ~1.05 TTM) and financing includes multiple convertible notes. Higher leverage and convertible obligations reduce balance-sheet flexibility, increase refinancing and dilution risk, and constrain capital allocation if operating performance lags the pro forma targets.
Elevated SG&A And Underperforming Legacy ProductsAcquisition-related SG&A increases and a new normalized operating run-rate roughly $500K/month create higher fixed costs just as some legacy consumer products underperformed (Silly George). That combination raises the break-even hurdle and makes timely integration and BioNX revenue realization critical to achieving sustained profitability.
NexGel Inc News
NXGL FAQ
What was NexGel Inc’s price range in the past 12 months?
NexGel Inc lowest stock price was $0.48 and its highest was $2.89 in the past 12 months.
What is NexGel Inc’s market cap?
NexGel Inc’s market cap is $6.12M.
When is NexGel Inc’s upcoming earnings report date?
NexGel Inc’s upcoming earnings report date is Aug 18, 2026 which is in 35 days.
How were NexGel Inc’s earnings last quarter?
Currently, no data Available
Is NexGel Inc overvalued?
According to Wall Street analysts NexGel Inc’s price is currently Undervalued.
Does NexGel Inc pay dividends?
NexGel Inc does not currently pay dividends.
What is NexGel Inc’s EPS estimate?
NexGel Inc’s EPS estimate is -0.12.
How many shares outstanding does NexGel Inc have?
NexGel Inc has 9,225,242 shares outstanding.
What happened to NexGel Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexGel Inc?
Currently, no hedge funds are holding shares in NXGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexGel Inc
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
NXGL Stock 12 Month Forecast
Average Price Target
$2.00
▲(21.95% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
Sanara MedTech
―
Femasys
―
Ownership Overview
4.73% Insiders
1.13% Mutual Funds
0.95% Other Institutional Investors
92.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---